The current good manufacturing practice (cGMP) compliant facility is located in Grenoble, France and will be operational from April 2010. Cell banking and manufacture of supplies for preclinical and clinical trials, at a scale of 100-200L, will take place at the facility.
PX'Therapeutics also plans to add a 100L bioreactor to its existing unit which is devoted to bacterial and yeast systems. By making these expansions PX'Therapeutics believes it can support strong growth, driven by big pharma partnerships, over the next two years.